Page last updated: 2024-12-11
hexahydrocurcumin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
hexahydrocurcumin: from Zingiber officinale; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Zingiber | genus | [no description available] | Zingiberaceae | A plant family of the order Zingiberales, subclass Zingiberidae, class Liliopsida. It includes plants which have both flavoring and medicinal properties such as GINGER; turmeric (CURCUMA), and cardamom (ELETTARIA).[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5318039 |
CHEMBL ID | 479650 |
CHEBI ID | 81358 |
SCHEMBL ID | 290121 |
MeSH ID | M0570802 |
Synonyms (24)
Synonym |
---|
MEGXP0_001211 |
1,7-bis(4-hydroxy-3-methoxyphenyl)-5-heptanol-3-one |
5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)heptan-3-one |
hexahydrocurcumin |
C17826 , |
chebi:81358 , |
CHEMBL479650 |
5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3-one |
(rs)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone |
36062-05-2 |
SCHEMBL290121 |
CS-4377 |
5-hydroxy-1,7-bis(4-hydroxy-3-methoxylphenyl)-3-heptanone |
DTXSID00415731 |
HY-N0929 |
3-heptanone, 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)- |
hexahydrocurcumin, analytical standard |
Q27155296 |
MS-26053 |
rnl5xj2ba7 , |
curcumin, hexahydro- |
unii-rnl5xj2ba7 |
5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone |
E80659 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" In this work, we aimed to perform a comparative evaluation of curcuminoids and their hydrogenated metabolites from a medicinal chemistry point of view, by determining a set of key pharmacokinetic parameters and evaluating antioxidant potential in relation to such properties." | ( Pharmacokinetics-Driven Evaluation of the Antioxidant Activity of Curcuminoids and Their Major Reduced Metabolites-A Medicinal Chemistry Approach. Balogh, GT; Fülöp, F; Girst, G; Hunyadi, A; Ötvös, SB, 2021) | 0.62 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"To investigate the effects of hexahydrocurcumin (HHC), and its combination with 5-fluorouracil (5-FU) on dimethylhydrazine (DMH)-induced colon cancer in rats." | ( Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. Chintana, PY; Srimuangwong, K; Suksamrarn, A; Tocharus, C; Tocharus, J, 2012) | 1.06 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Though numerous reasons contribute to the low bioavailability of curcumin, one of the important reasons is associated with biotransformation of curcumin through either conjugation or reduction depending on curcumin administration route." | ( Structural Interactions of Curcumin Biotransformed Molecules with the N-Terminal Residues of Cytotoxic-Associated Gene A Protein Provide Insights into Suppression of Oncogenic Activities. Roy, BK; Singh, D; Srivastava, AK, 2017) | 0.46 |
" However, little is known about variations in its pharmacokinetics and tissue bioavailability between formulations." | ( Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers. Asher, GN; Dossou, KS; Hawke, RL; Kashuba, AD; Moaddel, R; Sandler, RS; Sanghvi, M; Xie, Y, 2017) | 0.46 |
" However, critical studies on its pharmacological and toxicological activities are needed to understand how this compound can have these biological functions considering its poor oral bioavailability and the low plasma concentration." | ( Biological and pharmacological effects of hexahydrocurcumin, a metabolite of curcumin. Cao, S; Fan, Y; Huang, Y; Kang, N; Qiu, F; Zhang, H; Zhang, Q, 2018) | 0.75 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Finally, once-daily dosing is sufficient to maintain detectable curcuminoids at steady state in both plasma and rectal tissues." | ( Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers. Asher, GN; Dossou, KS; Hawke, RL; Kashuba, AD; Moaddel, R; Sandler, RS; Sanghvi, M; Xie, Y, 2017) | 0.46 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
diarylheptanoid | A family of plant metabolites with a common 1,7-diphenylheptane structural skeleton, carrying various substituents. They are mainly distributed in the roots, rhizomes and bark of Alpinia, Zingiber, Curcuma and Alnus species. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (15)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1063389 | Inhibition of recombinant BACE1 (unknown origin) at 1.3 mM | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Synthesis and evaluation of curcumin derivatives toward an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1. |
AID421738 | Cytotoxicity against rat RBL2H3 cells at 200 uM after 12 hrs by MTT assay | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Antiallergic potential on RBL-2H3 cells of some phenolic constituents of Zingiber officinale (ginger). |
AID466918 | Antitrypanosomal activity against diminazene-resistant Trypanosoma brucei brucei deltaTbat1-KO after 48 hrs by alamar blue assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. |
AID515080 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 24 hrs by microtiter alamar blue assay | 2010 | European journal of medicinal chemistry, Oct, Volume: 45, Issue:10 | Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. |
AID421737 | Cytotoxicity against rat RBL2H3 cells after 12 hrs by MTT assay | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Antiallergic potential on RBL-2H3 cells of some phenolic constituents of Zingiber officinale (ginger). |
AID466922 | Cytotoxicity against HEK293 cells after 16 hrs by alamar blue assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. |
AID466921 | Antileishmanial activity against Leishmania mexicana MNYC/BZ/62/M379 amastigotes after 48 hrs by alamar blue assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. |
AID466917 | Antitrypanosomal activity against Trypanosoma brucei brucei 427 after 48 hrs by alamar blue assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. |
AID421743 | Antiallergic activity in mIgE-DNP and DNP-BSA-stimulated rat RBL2H3 cells assessed as inhibition of beta-hexosaminidase release at 200 uM pretreated before mIgE-DNP challenge | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Antiallergic potential on RBL-2H3 cells of some phenolic constituents of Zingiber officinale (ginger). |
AID466920 | Antileishmanial activity against Leishmania major Friedlin promastigotes after 48 hrs by alamar blue assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. |
AID421744 | Antiallergic activity in mIgE-DNP and DNP-BSA-stimulated rat RBL2H3 cells assessed as inhibition of beta-hexosaminidase release pretreated before mIgE-DNP challenge measured after 12 to 48 hrs | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Antiallergic potential on RBL-2H3 cells of some phenolic constituents of Zingiber officinale (ginger). |
AID466919 | Antitrypanosomal activity against multidrug-resistant Trypanosoma brucei brucei B48 after 48 hrs by alamar blue assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. |
AID367267 | Inhibition of Spiroplasma sp. MQ-1 M.SssI up to 100 uM | 2009 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 | Curcumin is a potent DNA hypomethylation agent. |
AID367265 | Inhibition of C1226 catalytic site of DNMT1 in presence of S-adenosyl methionine | 2009 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 | Curcumin is a potent DNA hypomethylation agent. |
AID367264 | Inhibition of C1226 catalytic site of DNMT1 | 2009 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 | Curcumin is a potent DNA hypomethylation agent. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (27)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (7.41) | 29.6817 |
2010's | 16 (59.26) | 24.3611 |
2020's | 9 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.53) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (3.70%) | 5.53% |
Reviews | 1 (3.70%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 25 (92.59%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |